leadf
logo-loader
NYSE:AIM

AIM ImmunoTech Inc

Receive alerts
Market:
NYSE
Market Cap:
$85.73 m
Price
2.16 USD
Change
4.35%
52 weeks high
7.05
52 weeks low
0.39

In brief

AIM ImmunoTech Inc. is an immuno-pharma company headquartered in Ocala, Florida and focused on the research and development of therapeutics to treat multiple types of cancers, as well as immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases.

Snapshot

A series of trials underway at major cancer research hospitals are evaluating the company's flagship cancer drug Ampligen